TCGA-FD-A6TD-01A-51R-A33J-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 12.68068331
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.630
- ALLOGRAFT_REJECTION+0.560
- COAGULATION+0.550
- INTERFERON_GAMMA_RESPONSE+0.550
- INFLAMMATORY_RESPONSE+0.510
- ANGIOGENESIS+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- IL6_JAK_STAT3_SIGNALING+0.460
- MYC_TARGETS_V2+0.460
- TNFA_SIGNALING_VIA_NFKB+0.460
Top 10 suppressed
- SPERMATOGENESIS-0.230
- PROTEIN_SECRETION-0.100
- HEDGEHOG_SIGNALING-0.080
- BILE_ACID_METABOLISM-0.070
- MYOGENESIS-0.060
- UV_RESPONSE_DN-0.060
- ANDROGEN_RESPONSE-0.050
- KRAS_SIGNALING_DN-0.040
- MITOTIC_SPINDLE-0.030
- PEROXISOME+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AE47BCDE-A2D2-43EF-8EC7-78E4D1817EEE | — | — | 0.947 |
| 2 | 5063882F-6377-4976-BB48-7275D46C44E6 | — | — | 0.942 |
| 3 | E00A399D-E6C3-439D-8E70-A7AD5DF5F5E2 | — | — | 0.931 |
| 4 | 8DA59514-8B25-493E-B226-818F2521B5D5 | — | — | 0.931 |
| 5 | TCGA-66-2765-01A-01R-0851-07 | — | cohortSQ1 | 0.928 |
| 6 | BS_D8N31T39 | low-grade glioma | — | 0.928 |
| 7 | TCGA-FD-A5C1-01A-11R-A28M-07 | — | — | 0.920 |
| 8 | TCGA-ZF-A9RD-01A-11R-A42T-07 | — | — | 0.920 |
| 9 | BS_M85CXHDV | high-grade glioma | — | 0.919 |
| 10 | F9A39954-57EB-4A3F-97A0-1801B08BBD53 | — | — | 0.917 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.630 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.560 | Idelalisib | — uncovered |
| COAGULATION | 0.550 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.550 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.510 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.460 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| COMPLEMENT | 0.430 | Inavolisib | — uncovered |
| APOPTOSIS | 0.400 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.380 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.310 | Inavolisib | — uncovered |